الفهرس 
Hepatocellular Carcinoma (HCC)Only 14 pages are availabe for public view
 |  | from | 176 |  |  |
| | | from | 176 | | |
Abstract
SUMMARY
H
epatocellular carcinoma HCC is now the sixth most common cause of cancer worldwide. The second leading cause of cancer death after lung cancer in men is HCC.
The most frequently used screening tests for HCC patients are hepatic ultrasound (US) with or without assessment of alpha-fetoprotein, but the diagnostic value of AFP is recently challenged due to its low sensitivity and specificity.
So the aim of this study was to evaluate the role of Glypican 3 as a diagnostic marker in HCC Egyptian patients.
The study was carried out on 60 Egyptian patients:
group 1( n:15) : patients without evidence of cirrhosis .
group 2 ( n:15) : patients with evidence of cirrhosis without HCC .
group 3(n: 15) : patients with liver cirrhosis and HCC with low alpha fetoprotein .
group 4(n: 15): patients with liver cirrhosis and HCC with high alpha fetoprotein .
For all participant in this study, full clinical assessment by history and physical examination in addition to laboratory hematological and biochemical assessment and confirmation of HCC diagnosis was done by triphasic CT on the abdomen, We assessed serum glypican 3 in all study participant.
The results showed, There was no significant correlation between GP3 and (age, DM, HTN, HB, WBS, platelet, AST, albumin, INR) among study groups.
While there was statistically significant positive correlation between GP3 and (BUN, total and direct bilirubin, ALT, AFP, child, MELD) among study groups.
The presence of (GP3) in blood, is a biomarker of early stages of HCC.
GP3 is a promising serum tumor marker for HCC diagnosis